Related Experiment Video

Updated: May 18, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

[Ranolazine in the treatment of chronic stable angina]

M Gustapane1, M T Cardillo, G Biasillo

  • 1Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Pol. A. Gemelli, Roma, Italia.

La Clinica Terapeutica
|September 12, 2012
PubMed

Insights

Coronary artery disease (CAD) and angina remain leading causes of death. Ranolazine offers a new add-on therapy for stable angina patients experiencing persistent symptoms despite optimal treatment.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Coronary artery disease (CAD) is a major cause of mortality in Europe and the US.
  • Angina is the primary symptom of stable CAD, impacting patient quality of life.
  • Current antianginal therapies (beta-blockers, calcium channel antagonists, nitrates) have limitations due to adverse effects and incomplete symptom relief.

Purpose:

  • To review the mechanism of action, tolerability, and clinical benefits of ranolazine.
  • To highlight ranolazine as a novel therapeutic option for stable angina management.

Summary:

  • Ranolazine is a new antianginal agent approved for add-on therapy in patients with stable angina.
  • It addresses the unmet need for patients who continue to experience angina despite optimal conventional treatment.
  • The review details ranolazine's pharmacological profile and its efficacy in improving anginal symptoms.

Impact:

  • Provides a valuable therapeutic option for patients with refractory angina.
  • Offers an alternative with a potentially different side-effect profile compared to traditional antianginal drugs.
  • Contributes to improving the management of stable coronary artery disease and enhancing patient outcomes.

More Related Videos

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...